Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancerGABRA, H; CAMERON, D. A; LEE, L. E et al.British journal of cancer. 1996, Vol 74, Num 12, pp 2008-2012, issn 0007-0920Article

Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogenLANGDON, S. P; GABRA, H; BARTLETT, J. M. S et al.Clinical cancer research. 1998, Vol 4, Num 9, pp 2245-2251, issn 1078-0432Article

High frequency of chromosome 9 deletion in ovarian cancer : evidence for three tumour-suppressor lociDEVLIN, J; ELDER, P. A; GABRA, H et al.British journal of cancer. 1996, Vol 73, Num 4, pp 420-423, issn 0007-0920Article

Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancerSHARMA, R; GRAHAM, J; MITCHELL, H et al.British journal of cancer. 2009, Vol 100, Num 5, pp 707-712, issn 0007-0920, 6 p.Article

WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclearGOURLEY, C; PAIGE, A. J. W; TAYLOR, K. J et al.International journal of oncology. 2005, Vol 26, Num 6, pp 1681-1689, issn 1019-6439, 9 p.Article

Loss of heterozygosity at 11q22 correlates with low progesterone receptor content in epithelial ovarian cancerGABRA, H; LANGDON, S. P; WATSON, J. E. V et al.Clinical cancer research. 1995, Vol 1, Num 9, pp 945-953, issn 1078-0432Article

Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized studyFOTOPOULOU, C; VERGOTE, I; BLAGDEN, S et al.Annals of oncology. 2014, Vol 25, Num 1, pp 160-165, issn 0923-7534, 6 p.Article

Expression of eEFI A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the EEFIA2 locusTOMLINSON, V. A. L; NEWBERY, H. J; ABBOTT, C. M et al.British journal of cancer. 2007, Vol 96, Num 10, pp 1613-1620, issn 0007-0920, 8 p.Article

Identification of a region of frequent loss of heterozygosity at 11q24 in colorectal cancerCONNOLLY, K. C; GABRA, H; MILLWATER, C. J et al.Cancer research (Baltimore). 1999, Vol 59, Num 12, pp 2806-2809, issn 0008-5472Article

Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumoursGABRA, H; TAYLOR, L; COHEN, B. B et al.British journal of cancer. 1995, Vol 72, Num 2, pp 367-375, issn 0007-0920Article

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancersVASEY, P. A; GORE, M; WILSON, R et al.British journal of cancer. 2008, Vol 98, Num 11, pp 1774-1780, issn 0007-0920, 7 p.Article

Malignant mixed mesodermal tumours: biology and clinical aspectsGOURLEY, C; AL-NAFUSSI, A; ABDULKADER, M et al.European journal of cancer (1990). 2002, Vol 38, Num 11, pp 1437-1446, issn 0959-8049Article

Intra-uterine death resulting from placental metastases in adenocarcinoma of unknown primaryGOURLEY, C; MONAGHAN, H; BEATTIE, G et al.Clinical oncology (Springer. Print). 2002, Vol 14, Num 3, pp 213-216, issn 0936-6555, 4 p.Article

High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer : a phase I/II studyCAMERON, D. A; CRAIG, J; GABRA, H et al.British journal of cancer. 1996, Vol 74, Num 12, pp 2013-2017, issn 0007-0920Article

Continuous 5-fluorouracil in the treatment of breast cancerCAMERON, D. A; GABRA, H; LEONARD, R. C. F et al.British journal of cancer. 1994, Vol 70, Num 1, pp 120-124, issn 0007-0920Article

c-myc oncogene expression in colorectal cancerSIKORA, K; CHAN, S; EVAN, G et al.Cancer. 1987, Vol 59, Num 7, pp 1289-1295, issn 0008-543XArticle

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancerGLASSPOOL, R. M; BROWN, R; GABRA, H et al.British journal of cancer. 2014, Vol 110, Num 8, pp 1923-1929, issn 0007-0920, 7 p.Article

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIGBANERJEE, S; RUSTIN, G; GILBY, E et al.Annals of oncology. 2013, Vol 24, Num 3, pp 679-687, issn 0923-7534, 9 p.Article

Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancerHARDING, V; FENU, E; GABRA, H et al.British journal of cancer. 2012, Vol 107, Num 6, pp 925-930, issn 0007-0920, 6 p.Article

A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcomaANG, J. E; SHAH, R. N; GABRA, H et al.Annals of oncology. 2009, Vol 20, Num 11, pp 1787-1793, issn 0923-7534, 7 p.Article

A prognostic model for ovarian cancerCLARK, T. G; STEWART, M. E; ALTMAN, D. G et al.British journal of cancer. 2001, Vol 85, Num 7, pp 944-952, issn 0007-0920Article

A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16DPAIGE, A. J. W; TAYLOR, K. J; STEWART, A et al.Cancer research (Baltimore). 2000, Vol 60, Num 6, pp 1690-1697, issn 0008-5472Article

A protective role for common P21^WAF1/Cip1 polymorphisms in human ovarian cancerMILNER, B. J; BROWN, I; GABRA, H et al.International journal of oncology. 1999, Vol 15, Num 1, pp 117-119, issn 1019-6439Article

Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosisGABRA, H; WATSON, J. E. V; TAYLOR, K. J et al.Cancer research (Baltimore). 1996, Vol 56, Num 5, pp 950-954, issn 0008-5472Article